When.com Web Search

Search results

  1. Results From The WOW.Com Content Network
  2. Biologics license application - Wikipedia

    en.wikipedia.org/wiki/Biologics_License_Application

    The biologics license application is a request for permission to introduce, or deliver for introduction, a biologic product into interstate commerce (21 CFR 601.2). The BLA is regulated under 21 CFR 600 – 680. A BLA is submitted by any legal person or entity who is engaged in manufacture or an applicant for a license who takes responsibility ...

  3. Title 21 of the Code of Federal Regulations - Wikipedia

    en.wikipedia.org/wiki/Title_21_of_the_Code_of...

    The 600 series covers biological products (e.g. vaccines, blood): 601 Licensing under section 351 of the Public Health Service Act; 606 et seq. cGMPs for human blood and blood products; The 700 series includes the limited regulations on cosmetics: 701 Labeling requirements; The 800 series are for medical devices: 803 Medical device reporting

  4. Biologics Price Competition and Innovation Act of 2009

    en.wikipedia.org/wiki/Biologics_Price...

    The Biologics Price Competition and Innovation Act of 2009 (BPCI Act) amends the Public Health Service Act (PHS Act) to create an abbreviated approval pathway for biological products shown to be biosimilar to, or interchangeable with, an FDA-licensed reference biological product.

  5. FDA Accepts Biogen Idec's Biologics License Application for ...

    www.aol.com/news/2013-05-13-fda-accepts-biogen...

    For premium support please call: 800-290-4726 more ways to reach us

  6. Complete Response Letter - Wikipedia

    en.wikipedia.org/wiki/Complete_Response_Letter

    In United States pharmaceutical regulatory practice, a Complete Response Letter (CRL), or more rarely, a 314.110 letter, is a regulatory action by the Food and Drug Administration in response to a New Drug Application, Amended New Drug Application or Biologics License Application, indicating that the application will not be approved in its present form. [1]

  7. Santarus and Pharming Announce Submission of RUCONEST ... - AOL

    www.aol.com/2013/04/17/santarus-and-pharming...

    Santarus and Pharming Announce Submission of RUCONEST Biologics License Application to FDA SAN DIEGO & LEIDEN, Netherlands--(BUSINESS WIRE)-- Santarus, Inc. (NAS: SNTS) and Pharming Group NV (NYSE ...

  8. Merck Announces FDA Acceptance of Biologics License ...

    www.aol.com/news/2013-05-08-merck-announces-fda...

    For premium support please call: 800-290-4726 more ways to reach us

  9. Marketing authorisation - Wikipedia

    en.wikipedia.org/wiki/Marketing_authorisation

    In most countries, a marketing authorisation is valid for a period of 5 years. After this period, one should apply for renewal of the marketing authorisation, usually by providing minimal data proving that quality, efficacy and safety characteristics are maintained and the risk-benefit ratio of the medicinal product is still favourable.